Regenxbio Company Profile (NASDAQ:RGNX)

Analyst Ratings

Consensus Ratings for Regenxbio (NASDAQ:RGNX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.25 (306.98% upside)

Analysts' Ratings History for Regenxbio (NASDAQ:RGNX)
Show:
DateFirmActionRatingPrice TargetActions
7/5/2016Piper Jaffray Cos.Reiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/12/2015Bank of America Corp.Initiated CoverageBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Regenxbio (NASDAQ:RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
6/6/2016        
5/5/2016($0.40)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regenxbio (NASDAQ:RGNX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Regenxbio (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Regenxbio (NASDAQ:RGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regenxbio (NASDAQ:RGNX)
DateHeadline
07/08/16 09:00 AMCould Regenxbio Shares Have 320% Upside?
07/07/16 01:17 PMThis Protocol Change Means Regenxbio Inc (RGNX) Can Finally Get Started On Its Gene Therapy Trial -
07/06/16 06:25 PMThis Protocol Change Means Regenxbio Inc (NASDAQ:RGNX) Can Finally Get Started On Its Gene Therapy Trial
07/05/16 03:21 PMREGENXBIO Provides Update on Lead Gene Therapy Development Programs - [at noodls] - Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia is actively recruiting and screening patients; expect to enroll first patient in second half of 2016 IND ...
06/20/16 02:08 PMETF’s with exposure to REGENXBIO, Inc. : June 20, 2016 -
06/01/16 03:31 PMREGENXBIO INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/30/16 01:53 PMREGENXBIO Inc. (NASDAQ:RGNX) Broker Price Targets For The Coming Week - Share Trading News - REGENXBIO Inc. (NASDAQ:RGNX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of REGENXBIO Inc. (NASDAQ:RGNX). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...Regenxbio Incorporated (NASDAQ:RGNX) Sellers Increased By 2.49% Their ShortsHNNall 2 news articles »
05/28/16 11:59 AMAre Analysts Bearish Regenxbio Inc (NASDAQ:RGNX) After Last Week? - Wall Street Hints and News - Are Analysts Bearish Regenxbio Inc (NASDAQ:RGNX) After Last Week?Wall Street Hints and NewsOut of 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Regenxbio has been the topic of 4 analyst reports since October 12, 2015 according to StockzIntelligence Inc. Below is a list ...
05/26/16 12:04 PMEarnings Review and Stock Rundown for Regenxbio Inc (NASDAQ:RGNX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Regenxbio Inc (NASDAQ:RGNX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Regenxbio Inc (NASDAQ:RGNX) to post ...and more »
05/25/16 11:35 AMBroker Roundup For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News - Broker Roundup For REGENXBIO Inc. (NASDAQ:RGNX)Share Trading News10/12/2015 – Bank of America Merrill Lynch began new coverage on REGENXBIO Inc. giving the company a “buy” rating. They now have a USD 29 price target on the stock. The share price of REGENXBIO Inc. (NASDAQ:RGNX) was down -2.35% during the ...
05/23/16 04:33 PMETF’s with exposure to REGENXBIO, Inc. : May 23, 2016 -
05/23/16 11:34 AMNext Weeks Broker Price Targets For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News - Next Weeks Broker Price Targets For REGENXBIO Inc. (NASDAQ:RGNX)Share Trading NewsREGENXBIO Inc. has a 50 day moving average of 11.25 and a 200 day moving average of 14.78. The stock's market capitalization is 317.37M, it has a 52-week low of 8.50 and a 52-week high of 32.00. The share price of the company (NASDAQ:RGNX) was ...
05/21/16 11:53 AMRegenxbio Incorporated (NASDAQ:RGNX) Short Interest Increased By 2.62% - Wall Street Hints and News - Regenxbio Incorporated (NASDAQ:RGNX) Short Interest Increased By 2.62%Wall Street Hints and NewsThe short interest to Regenxbio Incorporated's float is 5.61%. The stock increased 1.09% or $0.13 on May 20, hitting $12.05. About 150,926 shares traded hands or 90.57% up from the average. Regenxbio Inc (NASDAQ:RGNX) has declined 36.14% since ...
05/21/16 11:53 AMHow Analysts Feel About Regenxbio Inc (NASDAQ:RGNX)? - Wall Street Hints and News - How Analysts Feel About Regenxbio Inc (NASDAQ:RGNX)?Wall Street Hints and NewsOut of 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Regenxbio has been the topic of 4 analyst reports since October 12, 2015 according to StockzIntelligence Inc. Below is a list ...Regenxbio Inc. (RGNX) Files Form 4 Insider Selling : Llc Fmr Sells 18300 SharesMarket Digestall 2 news articles »
05/21/16 11:53 AMRevenue Update on Regenxbio Inc(NASDAQ:RGNX) - Trade Calls - Revenue Update on Regenxbio Inc(NASDAQ:RGNX)Trade CallsRegenxbio Inc(NASDAQ:RGNX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $393.00K. Analysts estimated a revenue of $2.02M. Earnings per share were ...
05/17/16 02:53 PMREGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 11:41 AMMix Wondering Stocks- Southwest Airlines (NYSE:LUV), Regenxbio (NASDAQ:RGNX), Williams Companies (NYSE ... - Seneca Globe - Seneca GlobeMix Wondering Stocks- Southwest Airlines (NYSE:LUV), Regenxbio (NASDAQ:RGNX), Williams Companies (NYSE ...Seneca GlobeRegenxbio Inc. (NASDAQ:RGNX) considered as an active stocks in active lead, shares moves up 7.94% to $12.24 as REGENXBIO reported that a license contract with Biogen (BIIB) for the development of gene therapy product candidates based on the NAV ...and more »
05/17/16 11:41 AMRegenxbio (RGNX), Biogen (BIIB) Enter Licensing Agreement for Gene Therapy Treatments - StreetInsider.com - FierceBiotechRegenxbio (RGNX), Biogen (BIIB) Enter Licensing Agreement for Gene Therapy TreatmentsStreetInsider.comREGENXBIO Inc. (Nasdaq: RGNX) announced an exclusive worldwide license agreement with Biogen (Nasdaq: BIIB) for the development of gene therapy product candidates based on the NAV Technology Platform for the treatment of two rare genetic vision ...Regenxbio, Biogen Sign Exclusive Deal to Treat Rare Genetic Vision Disorders; Shares Flat in Pre Market (NASDAQ ...Sonoran Weekly ReviewREGENXBIO inks license deal with Biogen for two AAV vectorsSeeking Alphaall 27 news articles »
05/16/16 09:55 AMAmgen signs licensing deal for Penn gene therapy technology -
05/16/16 06:32 AMREGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders - [at noodls] - ROCKVILLE, Md., May 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated ...
05/10/16 11:25 AMAfter Last Week What Do Analysts Think Of REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News - After Last Week What Do Analysts Think Of REGENXBIO Inc. (NASDAQ:RGNX)Share Trading NewsThey now have a USD 29 price target on the stock. The share price of REGENXBIO Inc. (NASDAQ:RGNX) was down -1.40% during the last trading session, with a day high of 10.20. 79390 shares were traded on REGENXBIO Inc.'s last session. The stock's 50 ...
05/07/16 10:39 AMEarnings Outlook on Regenxbio Inc (NASDAQ:RGNX) - B.O.D.Y Confidential - Earnings Outlook on Regenxbio Inc (NASDAQ:RGNX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Regenxbio Inc (NASDAQ:RGNX)'s next earnings release which is expected to be posted on or around 2016-06-02. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.45 for ...and more »
05/05/16 11:19 AMLatest Analyst Ratings For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News - Latest Analyst Ratings For REGENXBIO Inc. (NASDAQ:RGNX)Share Trading NewsREGENXBIO Inc. has a 50 day moving average of 11.17 and a 200 day moving average of 15.17. The stock's market capitalization is 273.13M, it has a 52-week low of 8.50 and a 52-week high of 32.00. The share price of the company (NASDAQ:RGNX) was ...
05/05/16 07:21 AMREGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights - [at noodls] - On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016 Progressing toward filing an IND with the U.S. Food ...
05/03/16 07:10 AMREGENXBIO to Participate in May Investor Conferences - [at noodls] - ROCKVILLE, Md., May 03, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated ...
05/02/16 11:40 AMStocks in News: Paragon Shipping (NASDAQ:PRGN), Regenxbio (NASDAQ:RGNX), 3M Company (NYSE:MMM ... - KC Register - Stocks in News: Paragon Shipping (NASDAQ:PRGN), Regenxbio (NASDAQ:RGNX), 3M Company (NYSE:MMM ...KC RegisterRegenxbio Inc. (NASDAQ:RGNX) announced that preclinical data from studies supported by REGENXBIO at the Perelman School of Medicine at the University of Pennsylvania will be presented in two poster sessions at the American Society of Gene & Cell ...
04/29/16 10:44 AMValeant revamps board, reveals government investigations -
04/28/16 12:42 PMETF’s with exposure to REGENXBIO, Inc. : April 28, 2016 -
04/28/16 10:49 AMSurprising Analyst 12-Month Target For IUSG - ... of IUSG's underlying holdings with notable upside to their analyst target prices are Lantheus Holdings Inc (LNTH), REGENXBIO Inc (RGNX), and Zafgen Inc (ZFGN). Although LNTH has traded at a recent price of $2.04/share, the average analyst target is ...
04/19/16 10:46 AMForm 8-K REGENXBIO Inc. For: Apr 19 - 2016 — REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV ® Technology Platform, today announced ...
04/19/16 07:25 AMPreclinical Data from REGENXBIO’s RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting - [at noodls] - High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degeneration Gene transfer mediated by RGX-121 shown to globally ...
03/30/16 10:02 AMFresh 52-week Lows at the Close – PBYI, VSLR, ORPN, HBHC, DAC, MNDO, LOV - The company traded at $21.70 – 0.50 (2.25 pct) on 1,057 total stock volume. Regenxbio Inc (RGNX) posted a new low of 8.50 above a previous 52 week low of 9.47. The company traded at $9.41 – 0.21 (2.18 pct) on 70,247 total stock volume. Gulf Island ...
03/29/16 10:04 AMETF’s with exposure to REGENXBIO, Inc. : March 29, 2016 -
03/16/16 09:55 AMREGENXBIO, Inc. :RGNX-US: Earnings Analysis: 2015 By the Numbers -
03/09/16 12:04 PMREGENXBIO INC. Financials -
03/07/16 09:38 AMIs the AveXis Inc (NASDAQ:AVXS) Decline a Discount Opportunity? - A company called Regenxbio Inc (NASDAQ:RGNX) developed and licensed the capsid element of the treatment to AveXis, and it’s this relationship that looks to be the only plausible driver behind the decline at the end of last week. Regenxbio reported a loss ...
03/03/16 07:16 AMREGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of -
03/03/16 07:16 AM8:16 am REGENXBIO reports Q4 results, revenue rose 286% YoY to $4.44 mln; co provides update on its clinical pipeline -
03/03/16 07:15 AMRegenxbio reports 4Q loss -
03/03/16 07:00 AMREGENXBIO Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Operational Progress - [GlobeNewswire] - Entered 2016 in strong financial position with more than $215 million in cash, cash equivalents and marketable securities; on track to advance multiple lead gene therapy product candidate programs into ...
03/01/16 07:00 AMREGENXBIO Announces Appointment of Faraz Ali as Chief Business Officer - [GlobeNewswire] - ROCKVILLE, Md., March 01, 2016-- REGENXBIO Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy based on ...
02/29/16 09:15 AMREGENXBIO : Joins Organizations Worldwide to Recognize Rare Disease Day® 2016 - ROCKVILLE, Md., February 29, 2016-- REGENXBIO Inc. (Nasdaq: RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV ...
02/22/16 08:45 AMAnalysts Anticipate IWN Will Reach $103 - Inc. (CALA), Arcadia Biosciences Inc (RKDA), and REGENXBIO Inc (RGNX). Although CALA has traded at a recent price of $5.59/share, the average analyst target is 132.56% higher at $13.00/share. Similarly, RKDA has 132.56% upside from the recent share price ...
02/10/16 08:40 AMOversold Conditions For REGENXBIO (RGNX) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of REGENXBIO Inc (RGNX) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $11.40 per share. By comparison ...
02/04/16 08:48 AMFirst two IPOs of 2016 trade up; IPO market continues its 3-year biotech run - It was the first biotech IPO to price above the midpoint since September's REGENXBIO (RGNX; -44%). However, the deal was supported by its largest shareholders, who committed to buying up 50% of the offering. Preclinical gene editing biotech Editas Medicine ...
02/02/16 08:20 AMMaking rare diseases rarer: Gene therapy biotech AveXis sets terms for $85 million IPO - AveXis licenses gene therapy technology from REGENXBIO ( RGNX), which popped 38% in its September 2015 IPO but now trades 37% below the offer price. AveXis was founded in 2010 and plans to list on the Nasdaq under the symbol AVXS. Goldman Sachs and ...
12/18/15 03:24 PMREGENXBIO Added to Russell 2000(R) Index - [at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced ...
12/13/15 10:22 AMShould You Buy TriCo Bancshares (TCBK)? -
12/01/15 08:11 AMREGENXBIO to Participate in Upcoming Investor and Scientific Conferences - [GlobeNewswire] - ROCKVILLE, Md. -- REGENXBIO Inc. , a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced ...
11/05/15 09:07 AMRegenxbio reports 3Q loss -

Social

About Regenxbio

Regenxbio logoREGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $8.17
  • 50 Day Moving Average: $8.67
  • 200 Day Moving Average: $11.23
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $215.18M
  • Current Year EPS Consensus Estimate: $-2.37 EPS
  • Next Year EPS Consensus Estimate: $-2.54 EPS
Additional Links:
Regenxbio (NASDAQ:RGNX) Chart for Saturday, July, 30, 2016